110 results
8-K
EX-10.1
NMRD
Nemaura Medical Inc
21 Sep 20
Nemaura Medical Appoints Justin Mclarney as Chief Finance Officer
4:10pm
Health and safety
21 Outside interests
22 Our documents
23 Our property
24 Confidential information
25 Public interest disclosure
26 Intellectual property … :
to assist in the performance of our health and safety obligations;
to assist us to assess whether any adaptation is needed to the workplace or working
8-K
EX-99.1
NMRD
Nemaura Medical Inc
19 Aug 20
Nemaura Medical issues Presentation Pertaining to the use of Continuous Glucose Monitoring in COVID-19 Patients
11:20am
the safety of medical professionals.
Both the CGM and CLM (continuous lactate monitoring) products are based on Nemaura’s BEAT™ platform, which … patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general
8-K
EX-99.1
NMRD
Nemaura Medical Inc
18 Mar 20
Nemaura To Prepare for Launch of sugarBEAT® CGM In the U.S. Following FDA Feedback
4:07pm
, but are not limited to, the launch of sugarBEAT® in the US, risks related to regulatory approvals and the success of Nemaura’s ongoing studies, including the safety … skin irritation or other adverse events from the device, as well as any misuse impacting patient safety. These and other risks and uncertainties
8-K
EX-99.2
NMRD
Nemaura Medical Inc
30 Mar 20
Regulation FD Disclosure
4:21pm
criteria: 1. Intended only for general wellness use 2. Presents a low risk to the safety of users and other persons. What is ‘General Wellness Use’? ‘(1 … that without controls could pose a risk to the safety of users and / or other persons. 13
References [1] Gallup Poll; November 2019 (https
424B5
NMRD
Nemaura Medical Inc
17 Dec 18
Prospectus supplement for primary offering
4:57pm
the device can be tested and evaluated for its clinical output, in this case the accuracy and safety with which it can trend blood glucose levels … and regulations, including those relating to the protection of the environment, health and safety. Some of the pertinent laws have not been definitively
424B5
8edbfzw zqc1
19 Dec 18
Prospectus supplement for primary offering
5:09pm
8-K
EX-99.1
2iny 47tpom9f0
23 Apr 19
Final step required prior to filing de novo application to the U.S. Food and Drug Administration
8:02am
8-K
EX-99.1
fbec elk4q
16 Apr 19
Enhances Product Capabilities in Advance of CE Mark Approval
11:41am
8-K
EX-99.1
710w2nmw1 3dc
13 Dec 23
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision
8:00am
8-K
EX-99.1
74odsbumtsq2
1 Aug 19
Nemaura Medical Inc. Announces $8 million Senior Debt Facility Provided by Existing Investors
8:42am
8-K
EX-99.1
dpyu 7j4syrx
11 Aug 23
Nemaura Medical Secures $6.5m in Non-Dilutive Funding
5:07pm
8-K
EX-99.1
jyumxq9
11 Feb 21
Nemaura Medical Secures $20 Million Non-Dilutive Loan
8:00am
8-K
EX-10.1
thb1j1hhu1fw962vszdj
2 Nov 20
Entry into a Material Definitive Agreement
12:00am
424B8
brchgi2s1jn 7ofgi9
11 Sep 23
Prospectus unintentially filed late
4:41pm